Tvardi Therapeutics cleared a concrete regulatory hurdle on November 19 when the FDA returned written pre-IND feedback on TTI-109, the company’s oral STAT3 inhibitor being developed for inflammatory bowel disease. That feedback, which Tvardi says it will use to finalize its IND package, is the specific thing separating the program from a first human IBD trial, and it arrived after Phase 1 data characterized TTI-109’s conversion to its active form and plasma concentration profile across repeat dosing.
The strategic bet here is on STAT3 as a shared driver across IBD subtypes. STAT3 sits downstream of several cytokine signals implicated in both Crohn’s disease and ulcerative colitis, which means a clean oral inhibitor could address disease biology that biologics hit indirectly and that patients must inject or infuse. Phase 1 results released earlier this year showed TTI-109, a phosphate prodrug of TTI-101, produced plasma exposures nearly identical to molar-equivalent doses of the parent compound, which simplified the dose-extrapolation argument Tvardi now takes into the IND.
Pre-IND meetings are Type B consultations, not approvals, so written FDA responses do not guarantee a smooth IND submission or a particular trial design. What they do give a small company is documented agency input it can cite if questions arise during review, giving the company documented agency input it can cite if questions arise during review. For Tvardi, which has prior clinical experience with the related compound TTI-101,, the IBD IND represents a formal positioning of the STAT3 platform for an immune-mediated indication, and the FDA’s written guidance now frames what that first IBD trial will need to show before dose escalation.
The practical question is what the FDA specifically required. The 8-K confirms written feedback was received and that the program is advancing toward IND filing. The IND submission date is the number to watch: when Tvardi files, the standard FDA review period begins, and that review period will shape the earliest possible timeline for dosing IBD patients.
Source link: https://www.sec.gov/Archives/edgar/data/1346830/000110465926129948/tm2630209d1_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.

